While searching for a non-invasive way to detect prostate cancer cells circulating in blood, Duke Cancer Institute researchers have identified some blood markers associated with tumor resistance to two common hormone therapies.
In a study published online this month in the journal Clinical Cancer Research, the authors reported that they isolated multiple key gene alterations in the circulating prostate tumor cells of patients who had developed resistance to abiraterone or enzalutamide.
“We have developed a method that allows us to examine the whole genome of rare circulating cancer cells in the blood, which is unique in each patient, and which can change over time during treatment.”
The study, focusing on a small number of patients, used blood analysis technology to demonstrate that circulating tumor cells detected in blood have the potential to reveal important genetic information that could guide treatments selection in the future, and suggest targets for new therapies.
“We have developed a method that allows us to examine the whole genome of rare circulating cancer cells in the blood, which is unique in each patient, and which can change over time during treatment,” says senior author Andrew Armstrong, MD, a medical oncologist and co-director of Genitourinary Clinical-Translational Research at the Duke Cancer Institute (DCI).
“Among the genomic changes in the patients’ individual cancers, we were able to find key similarities between the cancer cells of men who have hormone-resistant prostate cancer,” Armstrong says. “Our goal is to develop a ‘liquid biopsy’ that would be non-invasive, yet provide information that could guide clinical decisions.”
Armstrong and colleagues from the DCI and the Duke Molecular Physiology Institute used array-based comparative genomic hybridization to analyze the genome of the circulating tumor cells of 16 men with advanced, treatment-resistant prostate cancer. The technique enabled them to determine which genes had extra copies and which regions were deleted.
“Our goal is to develop a ‘liquid biopsy’ that would be non-invasive, yet provide information that could guide clinical decisions.”
Focusing both on genes that have previously been implicated in tumor progression, plus other genes important to cancer biology, the researchers found changes in multiple genetic pathways that appear to be in common among the men’s circulating tumor cells. “Our research provides evidence supporting the ability to measure gains and losses of large scale sections of the circulating tumor cells genome in men with prostate cancer,” says co-author Simon Gregory, PhD, director of the Section of Genomics and Epigenetics in the Duke Molecular Physiology Institute. “We are now evaluating this method combined with higher resolution DNA mutational studies and measurements of RNA splice variants in CTCs to determine their clinical relevance to patients and treatment resistance.”